The greatest response was observed in patients who harbored tumor PD‐L1 expression greater than 50% but was extended to those with expression >1%.13 Further studies, specifically the Keynote 024, demonstrated that pembrolizumab as a first‐line agent had greater efficacy compared with conventional chemotherapy in patients with PD‐L1 > 50%, similar to previous results.14 Here, CD274 is linked to neoplasm.